Waters Corporation (WAT) - Q1 2009 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended April 4, 2009. Waters Corporation is a global manufacturer of analytical instrument systems, including high performance liquid chromatography (HPLC), ultra performance liquid chromatography (UPLC), and mass spectrometry (MS) instruments, as well as thermal analysis and rheometry systems. The company operates through two primary divisions: the Waters Division and the TA Division.
Key Financial Metrics
| Metric | Q1 2009 | Q1 2008 |
|---|---|---|
| Total Net Sales | $333.1 million | $371.7 million |
| Gross Profit | $205.6 million | $216.3 million |
| Gross Margin | 61.7% | 58.2% |
| Operating Income | $85.5 million | $88.4 million |
| Net Income | $73.3 million | $68.5 million |
| Diluted EPS | $0.75 | $0.67 |
| Operating Cash Flow | $80.7 million | $95.9 million |
| Cash & Equivalents (End of Period) | $388.2 million | $700.6 million |
| Total Debt (Short + Long Term) | $588.1 million | $536.1 million |
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 10% year-over-year, driven by a 20% decline in instrument system sales due to global recessionary conditions and a 5% negative impact from foreign currency translation. Conversely, recurring service and consumable sales increased 3%.
- Profitability Expansion: Despite lower sales, Net Income increased 7% and Diluted EPS grew 12%. This was driven by a favorable sales mix shift toward higher-margin consumables and services, cost reduction initiatives, lower interest expense, and a significant tax benefit.
- Tax Benefit: The effective tax rate dropped to 11.9% from 18.6%, primarily due to a $5 million tax benefit from the reversal of a prior provision related to foreign legal entity reorganization.
- Acquisition: The company acquired Thar Instruments, Inc. for $36 million in cash (plus assumed debt) in February 2009, adding supercritical fluid chromatography technology to its portfolio.
- Debt Levels: Total debt increased by approximately $52 million as the company utilized its credit facility to fund the Thar acquisition and working capital needs.
Outlook, Risks, and Management Commentary
- Market Conditions: Management attributes the sales decline to reduced spending by pharmaceutical and industrial customers due to the global economic recession. Sales to government and academic customers increased 13%.
- Geographic Impact: Sales declines were broad-based, with Europe down 17% and the Rest of World down 16%, heavily impacted by currency translation. U.S. sales declined 6%.
- Liquidity: Management believes cash, cash equivalents ($431 million including short-term investments), and borrowing capacity are sufficient to fund operations, capital spending, and share repurchases for at least the next 12 months.
- Share Repurchases: The Board authorized a new $500 million share repurchase program in February 2009. The company repurchased $62 million of stock in the quarter.
- Legal Proceedings: The company is involved in patent litigation with Agilent Technologies in France and Germany. A $6 million payment was made in Q1 2009 regarding the French case. A securities class action lawsuit filed in November 2008 regarding alleged misrepresentations of revenue and earnings is ongoing.
Investor Verification Checklist
- Recurring Revenue Resilience: Verify the sustainability of the 3% growth in service and consumable sales as a buffer against cyclical instrument demand.
- One-Time Tax Impact: Confirm the non-recurring nature of the $5 million tax benefit and its effect on the reported 11.9% effective tax rate.
- Acquisition Integration: Monitor the integration of Thar Instruments and its projected contribution of $20 million in sales for the full year 2009.
- Legal Exposure: Track the status of the Agilent patent litigation in Germany and the Dearborn Heights securities class action.
- Currency Sensitivity: Assess the ongoing impact of the strengthening U.S. dollar on international sales, which negatively impacted revenue by 5% in this quarter.